Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Micron Technology (MU) received the most dramatic target price revision of the day. DA Davidson analyst Gil Luria raised his target to $3,000 from $2,100, a 43% increase. The move reflects growing confidence in AI-driven memory demand. With Japan's foreign machine tool orders up 66% year-on-year in August (Japan Machine Tool Builders' Association data), capital spending across the industrial and tech supply chain is accelerating.
Marvell Technology also drew attention. Cantor Fitzgerald's C.J. Muse lifted his target to $350 from $330, keeping a Hold rating. Consensus targets for Marvell moved to $322 across multiple analyst changes today, up from $309 previously. The semiconductor names are drawing broad upward revisions.
Palantir saw its consensus target rise to $199.84 from $195.57. Buy ratings outnumber sells by three to one.
Barclays made two contrasting healthcare calls. The bank initiated Baxter International at Sell with a $20 target, a bearish read on the medical products group. In the same move, it initiated Abbott Laboratories at Buy with a $120 target. Abbott has 23 Buy ratings from analysts, with just four Holds and no Sells.
KKR and Blackstone both saw small consensus target trims. Both remain Buy-leaning overall, but private equity valuations face scrutiny as captive finance recoveries rose 44% year-on-year in Q2 2026 (ORTEX alt data), pointing to rising credit stress in leveraged loan books.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
